Publikationen

The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy.

Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, Shariat SF.

Eur Urol. 2012 Feb;61(2):245-53. doi: 10.1016/j.eururo.2011.09.017. Epub 2011 Sep 28.

PMID:21975249


Prognostic factors for upper urinary tract urothelial carcinoma.

Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, Shariat SF; Medscape.

Nature Rev Urol. 2011 Jul 5;8(8):440-7. doi: 10.1038/nrurol.2011.96. Review.

PMID:21727942


Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers.

Shariat SF, Chromecki TF (co-first), Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y.

J Urol. 2012 Feb;187(2):457-62. doi: 10.1016/j.juro.2011.10.031. Epub 2011 Dec 15.

PMID:22177145


Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.

Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JI, Brisuda A, Babjuk M, Pummer K, Shariat SF.

BJU Int. 2013 Feb;111(2):249-55. doi: 10.1111/j.1464-410X.2012.11322.x. Epub 2012 Jun 21.

PMID:22727036


Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.

Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF.

BJU Int. 2012 Jul;110(1):63-8. doi: 10.1111/j.1464-410X.2011.10703.x. Epub 2011 Nov 11.

PMID:22077633


Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, Shariat SF.

World J Urol. 2012 Dec;30(6):753-9. doi: 10.1007/s00345-011-0772-2. Epub 2011 Oct 19.

PMID:2200911


Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy.

Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, Ng C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Bastian PJ, Martínez-Salamanca JI, Scherr DS, Shariat SF.

World J Urol. 2011 Aug;29(4):473-80. doi: 10.1007/s00345-011-0677-0. Epub 2011 Apr 17.

PMID:21499902


Stage pT0 after radical cystectomy: are all patients equal?

Chromecki TF, Cha EK, Shariat SF; Bladder Cancer Research Consortium.

Eur Urol. 2011 Sep;60(3):603-4. doi: 10.1016/j.eururo.2011.05.050. Epub 2011 Jun 7. No abstract available.

PMID:21665358


Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.

Shariat SF, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ.

Cancer. 2011 Jul 1;117(13):2892-7. doi: 10.1002/cncr.25903. Epub 2011 Jan 10.

PMID:21692050


Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma.

Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, Shariat SF.

J Urol. 2011 Jul;186(1):66-72. doi: 10.1016/j.juro.2011.03.031. Epub 2011 May 14.

PMID:21571333


Impact of Clinical and Histopathological Parameters on Disease Specific Survival in Patients with Collecting Duct Renal Cell Carcinoma: Development of a Disease Specific Risk Model.

May M, Ficarra V, Shariat SF, Zigeuner R, Chromecki T, Cindolo L, Burger M, Gunia S, Feciche B, Wenzl V, Aziz A, Chun F, Becker A, Pahernik S, Simeone C, Longo N, Zucchi A, Antonelli A, Mirone V, Stief C, Novara G, Brookman-May S; Members of the CORONA and SATURN projects, and the Young Academic Urologists Renal Cancer Group.

J Urol. 2013 Feb 19. doi:pii: S0022-5347(13)00305-4. 10.1016/j.juro.2013.02.035. [Epub ahead of print]

PMID:23434943


Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients.

Pichler M, Hutterer GC, Stoeckigt C, Chromecki TF, Stojakovic T, Golbeck S, Eberhard K, Gerger A, Mannweiler S, Pummer K, Zigeuner R.

Br J Cancer. 2013 Mar 5;108(4):901-7. doi: 10.1038/bjc.2013.28. Epub 2013 Feb 5.

PMID:23385728


Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis.

Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joual A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, Shariat SF.

Eur Urol. 2012 Jul 20. [Epub ahead of print]

PMID:22877503


Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project).

Brookman-May S, May M, Shariat SF, Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; members of the CORONA project and the SATURN project.

Eur Urol. 2012 Jun 22. [Epub ahead of print]

PMID:22748912


Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery.

Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, Shariat SF; Bladder Cancer Research Consortium (BCRC); Upper Tract Urothelial Carcinoma Collaboration (UTUCC).

Eur Urol. 2012 Oct;62(4):677-84. Epub 2012 Feb 15.

PMID:22349570


Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.

Cha EK, Shariat SF, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V.

Eur Urol. 2012 Apr;61(4):818-25. doi: 10.1016/j.eururo.2012.01.021. Epub 2012 Jan 23.

PMID: 22284969


Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma.

Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, Shariat SF.

J Urol. 2012 Mar;187(3):845-51. doi: 10.1016/j.juro.2011.10.158. Epub 2012 Jan 15.

PMID:22248522


Prognostic value of the Leibovich prognosis score supplemented by vascular invasion for clear cell renal cell carcinoma.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Groselj-Strele A, Kampel-Kettner K, Pummer K, Zigeuner R.

J Urol. 2012 Mar;187(3):834-9. doi: 10.1016/j.juro.2011.10.155. Epub 2012 Jan 15.

PMID:22245331


Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment.

Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M.

Eur Urol. 2012 Feb;61(2):237-42. doi: 10.1016/j.eururo.2011.10.011. Epub 2011 Oct 21.

PMID:22033174


Collecting system invasion and Fuhrman grade but not tumor size facilitate prognostic stratification of patients with pT2 renal cell carcinoma.

Brookman-May S, May M, Zigeuner R, Shariat SF, Scherr DS, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wieland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pahernik S; CORONA Project (Collaborative Research on Renal Neoplasms Association).

J Urol. 2011 Dec;186(6):2175-81. doi: 10.1016/j.juro.2011.07.105. Epub 2011 Oct 19.

PMID:22014800


External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, Pummer K, Zigeuner R.

J Urol. 2011 Nov;186(5):1773-7. doi: 10.1016/j.juro.2011.07.034. Epub 2011 Sep 25.

PMID:21944989


Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner.

Shariat SF, Chromecki TF, Hoefer J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT.

J Urol. 2011 Nov;186(5):2107-14. doi: 10.1016/j.juro.2011.06.048. Epub 2011 Sep 23.

PMID:21944124


External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.

Zigeuner R, Hutterer G, Chromecki T, Imamovic A, Kampel-Kettner K, Rehak P, Langner C, Pummer K.

Eur Urol. 2010 Jan;57(1):102-9. doi: 10.1016/j.eururo.2008.11.033. Epub 2008 Nov 28.

PMID:19062157


Tumor necrosis as prognostic indicator in transitional cell carcinoma of the upper urinary tract.

Langner C, Hutterer G, Chromecki T, Leibl S, Rehak P, Zigeuner R.

J Urol. 2006 Sep;176(3):910-3; discussion 913-4.

PMID:16890651


pT classification, grade, and vascular invasion as prognostic indicators in urothelial carcinoma of the upper urinary tract.

Langner C, Hutterer G, Chromecki T, Winkelmayer I, Rehak P, Zigeuner R.

Mod Pathol. 2006 Feb;19(2):272-9.

PMID:16424895


Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database.

May M, Aziz A, Zigeuner R, Chromecki T, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Coman I, Truss M, Dalpiaz O, Hoschke B, Gilfrich C, Feciche B, Stoltze A, Fenske F, Fritsche HM, Figenshau RS, Madison K, Sánchez-Chapado M, Martin MD, Salzano L, Lotrecchiano G, Joniau S, Waidelich R, Stief C, Brookman-May S; Members of the CORONA project the Young Academic Urologists Renal Cancer Group.

World J Urol. 2013 Apr 9. [Epub ahead of print]

PMID:23568445


Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study.

Cindolo L, Chiodini P, Brookman-May S, De Cobelli O, May M, Squillacciotti S, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Wirth MP, Dalpiaz O, Chromecki TF, Shariat SF, Sanchez-Chapado M, Del Carmen Santiago Martin M, Rocco B, Salzano L, Lotrecchiano G, Berardinelli F, Schips L.

BJU Int. 2013 Mar 7. doi: 10.1111/j.1464-410X.2012.11670.x. [Epub ahead of print]

PMID:23470199


Predictive ability of the 2002 and 2010 versions of the Tumour-Node-Metastasis classification system regarding metastasis-free, cancer-specific and overall survival in a European renal cell carcinoma single-centre series.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Groselj-Strele A, Pummer K, Zigeuner R.

BJU Int. 2013 Apr;111(4 Pt B):E191-5. doi: 10.1111/j.1464-410X.2012.11584.x. Epub 2012 Oct 26.

PMID:23107473


Comparison of the 2002 and 2010 TNM classification systems regarding outcome prediction in clear cell and papillary renal cell carcinoma.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Groselj-Strele A, Hoefler G, Pummer K, Zigeuner R.

Histopathology. 2013 Jan;62(2):237-46. doi: 10.1111/his.12001. Epub 2012 Sep 28.

PMID:23020176


Presence and extent of histological tumour necrosis is an adverse prognostic factor in papillary type 1 but not in papillary type 2 renal cell carcinoma.

Pichler M, Hutterer GC, Chromecki TF, Pummer K, Mannweiler S, Zigeuner R.

Histopathology. 2013 Jan;62(2):219-28. doi: 10.1111/j.1365-2559.2012.04328.x. Epub 2012 Sep 7.

PMID:22957986


Does preoperative platelet count and thrombocytosis play a prognostic role in patients undergoing nephrectomy for renal cell carcinoma? Results of a comprehensive retrospective series.

Brookman-May S, May M, Ficarra V, Kainz MC, Kampel-Kettner K, Kohlschreiber S, Wenzl V, Schneider M, Burger M, Wieland WF, Otto W, Tilki D, Gilfrich C, Hohenfellner M, Pahernik S, Chromecki TF, Stief C, Zigeuner R; Members of the CORONA (Collaborative Research On Renal Neoplasms Association) Project.

World J Urol. 2012 Aug 19. [Epub ahead of print]

PMID:22903790


Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Eberhard K, Hoefler G, Pummer K, Zigeuner R.

J Clin Pathol. 2012 Aug;65(8):721-4. doi: 10.1136/jclinpath-2012-200797. Epub 2012 May 25.

PMID:22639409


International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis.

Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, Shariat SF.

BJU Int. 2012 Sep;110(5):674-81. doi: 10.1111/j.1464-410X.2012.10930.x. Epub 2012 Feb 20.

PMID:22348322


Histologic tumor necrosis is an independent prognostic indicator for clear cell and papillary renal cell carcinoma.

Pichler M, Hutterer GC, Chromecki TF, Jesche J, Kampel-Kettner K, Rehak P, Pummer K, Zigeuner R.

Am J Clin Pathol. 2012 Feb;137(2):283-9. doi: 10.1309/AJCPLBK9L9KDYQZP.

PMID:22261455


Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study.

Martinez-Salamanca JI, Shariat SF, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G.

BJU Int. 2012 Apr;109(8):1155-61. doi: 10.1111/j.1464-410X.2011.10479.x. Epub 2011 Aug 24.

PMID:21883847


Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial.

Barbieri CE, Cha EK, Chromecki TF, Dunning A, Lotan Y, Svatek RS, Scherr DS, Karakiewicz PI, Sun M, Mazumdar M, Shariat SF.

BJU Int. 2012 Mar;109(5):685-90. doi: 10.1111/j.1464-410X.2011.010419.x. Epub 2011 Aug 18.

PMID:21851550


Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy.

Youssef RF, Shariat SF, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V.

Urol Oncol. 2011 Jun 23. [Epub ahead of print]

PMID:21704538


No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study.

Burger M, Shariat SF, Fritsche HM, Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V, Kassouf W, Seitz C, Pycha A, Tritschler S, Walton TJ, Novara G.

World J Urol. 2011 Aug;29(4):465-72. doi: 10.1007/s00345-011-0705-0. Epub 2011 Jun 1.

PMID:21630120


Laparoscopic partial nephrectomy: a matched-pair comparison of the transperitoneal versus the retroperitoneal approach.

Marszalek M, Chromecki T, Al-Ali BM, Meixl H, Madersbacher S, Jeschke K, Pummer K, Zigeuner R.

Urology. 2011 Jan;77(1):109-13. doi: 10.1016/j.urology.2010.02.057.

PMID:20970830


Inflammatory myofibroblastic tumour of the urinary bladder mimicking recurrent uterine carcinosarcoma.

Pristauz G, Moinfar F, Chromecki T, Bader AA, Winter R, Tamussino K.

Histopathology. 2009 Mar;54(4):490-3. doi: 10.1111/j.1365-2559.2009.03253.x. No abstract available.

PMID:19309402


Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location.

Zigeuner RE, Hutterer G, Chromecki T, Rehak P, Langner C.

BJU Int. 2006 Dec;98(6):1181-6.

PMID:17125475


CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T, Langner C.

Virchows Arch. 2007 Jan;450(1):59-64. Epub 2006 Nov 17.

PMID:17111129


Patterns of invasion and histological growth as prognostic indicators in urothelial carcinoma of the upper urinary tract.

Langner C, Hutterer G, Chromecki T, Rehak P, Zigeuner R.

Virchows Arch. 2006 May;448(5):604-11. Epub 2006 Mar 9.

PMID:16525827


Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression.

Langner C, Rupar G, Leibl S, Hutterer G, Chromecki T, Hoefler G, Rehak P, Zigeuner R.

Virchows Arch. 2006 Mar;448(3):325-30. Epub 2005 Nov 29.

PMID:16315020


Predictive factors of recurrence and survival of upper tract urothelial carcinomas.

Verhoest G, Shariat SF, Chromecki TF, Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Rouprêt M, Scherr DS, Bensalah K.

World J Urol. 2011 Aug;29(4):495-501. doi: 10.1007/s00345-011-0710-3. Epub 2011 Jun 17. Review.

PMID:21681525


Impact of gender on bladder cancer incidence, staging, and prognosis.

Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, Shariat SF.

World J Urol. 2011 Aug;29(4):457-63. doi: 10.1007/s00345-011-0709-9. Epub 2011 Jun 9. Review.

PMID:21656173


Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).

Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.

BJU Int. 2012 Apr;109(7):968-85. doi: 10.1111/j.1464-410X.2011.10643.x. Epub 2011 Oct 28. Review.

PMID:22035221


Essentials and Updates in Urologic Oncology (Nephrology Research and Clinical Developments) [Hardcover]

Philippe E. Spiess (Editor), Mathew Biagioli (Editor), Mayer Fishman (Editor), Jorge Lockhart (Editor), Julio M. Pow-Sang (Editor)

Hardcover: 858 pages

Publisher: Nova Science Publishers; 1 edition (May 2013)

Language: English

ISBN-10: 1620814943

ISBN-13: 978-1620814949


Chapter 19-Diagnosis and Treatment of Upper Tract Urothelial Carcinoma

(Thomas F. Chromecki, Vitaly Margulis, and Shahrokh F. Shariat) pp. 409-430

Impressum

Priv. Doz. Dr. Thomas Chromecki
Franckstraße 21
8010 Graz
+43 660 6382 900